RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

Inclusion Criteria * Patient \> 18 years old * Histologically confirmed diagnosis of melanoma * Previously treated or previously untreated metastatic melanoma by AJCC staging criteria * Presence of an index lesion \> 1 cm amenable to hypofractionated radiotherapy and at least one other additional lesion that can be followed for response using RECIST criteria * ECOG Performance status 0 or 1 * Signed informed consent document * Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment) Exclusion Criteria * Prior systemic therapy within 14 days of study enrollment. Patients must be adequately recovered from prior systemic therapy side effects as deemed by the PI. * Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc) * Presence or history of central nervous system metastasis (including brain) * Long-term use of systemic corticosteroids * Prior RT that precludes the delivery of hypofractionated radiotherapy